Zobrazeno 1 - 10
of 138
pro vyhledávání: '"Sander van Deventer"'
Autor:
Raygene Martier, Marina Sogorb-Gonzalez, Janice Stricker-Shaver, Jeannette Hübener-Schmid, Sonay Keskin, Jiri Klima, Lodewijk J. Toonen, Stefan Juhas, Jana Juhasova, Zdenka Ellederova, Jan Motlik, Eva Haas, Sander van Deventer, Pavlina Konstantinova, Huu Phuc Nguyen, Melvin M. Evers
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 15, Iss , Pp 343-358 (2019)
Spinocerebellar ataxia type 3 (SCA3), or Machado-Joseph disease (MJD), is a progressive neurodegenerative disorder caused by a CAG expansion in the ATXN3 gene. The expanded CAG repeat is translated into a prolonged polyglutamine repeat in the ataxin-
Externí odkaz:
https://doaj.org/article/9b77ea2f73b84aa0bf0e991ed509f3df
Autor:
Guus Sturk, Menno V. Huisman, Marjolein Peters, Giuseppe Avvisati, Paolo Prandoni, Harry R. Büller, Giancarlo Agnelli, Sander van Deventer, Eric A. van Royen, Marcel Levi, Cees Breederveld
Jan Wouter was born in Amsterdam and studied medicine at the University of Amsterdam, specialized in internal medicine, and defended his PhD thesis in 1971 with the subject 'Platelet functions in relation to haemostasis'. He became head of the depart
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1194c1871a7bcd41118a5a9073c33601
https://hdl.handle.net/1887/3230164
https://hdl.handle.net/1887/3230164
Publikováno v:
Nature biotechnology. 39(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::532a87c8d80c25f5d96535087723e0d7
https://pubmed.ncbi.nlm.nih.gov/33589817
https://pubmed.ncbi.nlm.nih.gov/33589817
Publikováno v:
Corporate IT Update (M2). 05/06/2010.
Publikováno v:
Corporate IT Update (M2). 05/06/2010.
Autor:
Anu, Acharya, Kate, Bingham, Jay, Bradner, Wylie, Burke, R Alta, Charo, Joel, Cherry, André, Choulika, Tony, Coles, Robert, Cook-Deegan, Stanley T, Crooke, Stanley T, Crook, Emilia, Díaz, Brent, Erickson, L Val, Giddings, Sebastian Eriksson, Giwa, James C, Greenwood, Vishal, Gulati, Sam, Hall, John, Harris, Jamie, Heywood, Colin, Hill, Jeremy, Levin, Adina, Mangubat, John, Maraganore, Giovanni, Mariggi, Barbara J, Mazur, Amy L, McGuire, Nathalie, Moll, Jonathan, Moreno, Gail, Naughton, Lita, Nelsen, Jane, Osbourn, Daniel, Perez, John, Reed, Eric, Schmidt, Vicki, Seyfert-Margolis, Paul, Stoffels, Jørgen, Thorball, Tara, O'Toole, Indrek, Vainu, Sander, van Deventer, Elias, Zerhouni, Daphne, Zohar
Publikováno v:
Nature Biotechnology. 34:276-283
A selection of individuals from the biotech ecosystem give their views on the challenges facing the sector over the coming years.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9d8f38a697bc316444d50c1c9397f62
https://doi.org/10.1038/nbt.3515
https://doi.org/10.1038/nbt.3515
Publikováno v:
Nature Biotechnology, 32(3), 213-216
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67bb6a7e27370bc15661a2ac76e54d47
https://pubmed.ncbi.nlm.nih.gov/24727767
https://pubmed.ncbi.nlm.nih.gov/24727767
Autor:
John, Ford, Matt, Lawson, David, Fowler, Nobuko, Maruyama, Seiji, Mito, Koichi, Tomiyasu, Shuji, Kinoshita, Chisa, Suzuki, Atsuhiro, Kawaguchi, Patrick, Round, Malcolm, Boyce, Steve, Warrington, Werner, Weber, Sander, van Deventer, John J P, Kastelein
Publikováno v:
British journal of clinical pharmacology. 78(3)
Two double-blind, randomized studies were conducted to assess the tolerability, pharmacokinetics and pharmacodynamics of oral TA-8995, a new cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.Study 1: Subjects received single do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::30a7fe470c888149caa33f5f290fd99d
https://pubmed.ncbi.nlm.nih.gov/24628035
https://pubmed.ncbi.nlm.nih.gov/24628035
Autor:
Ilaria Zanella, Pavlina Konstantinova, Sander van Deventer, Alexia Spoerl, Michael R. Hayden, Jana Miniarikova, Nicole Déglon, Amber L. Southwell, Harald Petry, Melvin M. Evers, Bas Blits, Virginie Zimmer
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 87:A91.3-A92
The most upstream therapeutic target in Huntington’s disease (HD) is the mutated huntingtin (mtHTT) and gene silencing with artificial miRNAs (miHTTs) delivered by adeno-associated viral vector (AAV) is expected to have therapeutic benefit. We have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c660013134a5f187f14f789b927b62af
https://doi.org/10.1136/jnnp-2016-314597.260
https://doi.org/10.1136/jnnp-2016-314597.260